GRAIL, Inc. Common Stock (GRALV) Stock Competitors & Peer Comparison
See (GRALV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRALV | $18.63 | +8.19% | 579.4M | N/A | N/A | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.76% |
| TMO | $488.59 | +5.30% | 174.3B | 25.76 | $18.21 | +0.39% |
| DHR | $188.21 | +5.62% | 126.7B | 34.70 | $5.16 | +0.76% |
| IDXX | $550.73 | +0.92% | 42.7B | 39.83 | $13.59 | N/A |
| A | $131.02 | +3.58% | 35.8B | 25.44 | $4.98 | +0.79% |
| NTRA | $259.72 | +13.51% | 33.6B | -144.91 | -$1.62 | N/A |
| IQV | $184.90 | +10.18% | 28.6B | 21.26 | $8.05 | N/A |
| ILMN | $176.10 | +9.12% | 25B | 29.99 | $5.50 | N/A |
| MTD | $1,208.42 | +3.81% | 23.4B | 27.16 | $42.60 | N/A |
Stock Comparison
GRALV vs DHR-PB Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GRALV is priced at $18.63, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GRALV's ROE is N/A, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GRALV is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check DHR-PB's competition here
GRALV vs TMO Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, TMO has a market cap of 174.3B. Regarding current trading prices, GRALV is priced at $18.63, while TMO trades at $488.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas TMO's P/E ratio is 25.76. In terms of profitability, GRALV's ROE is N/A, compared to TMO's ROE of +0.13%. Regarding short-term risk, GRALV is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check TMO's competition here
GRALV vs DHR Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DHR has a market cap of 126.7B. Regarding current trading prices, GRALV is priced at $18.63, while DHR trades at $188.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DHR's P/E ratio is 34.70. In terms of profitability, GRALV's ROE is N/A, compared to DHR's ROE of +0.07%. Regarding short-term risk, GRALV is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check DHR's competition here
GRALV vs IDXX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, IDXX has a market cap of 42.7B. Regarding current trading prices, GRALV is priced at $18.63, while IDXX trades at $550.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas IDXX's P/E ratio is 39.83. In terms of profitability, GRALV's ROE is N/A, compared to IDXX's ROE of +0.71%. Regarding short-term risk, GRALV is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check IDXX's competition here
GRALV vs A Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, A has a market cap of 35.8B. Regarding current trading prices, GRALV is priced at $18.63, while A trades at $131.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas A's P/E ratio is 25.44. In terms of profitability, GRALV's ROE is N/A, compared to A's ROE of +0.21%. Regarding short-term risk, GRALV is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check A's competition here
GRALV vs NTRA Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NTRA has a market cap of 33.6B. Regarding current trading prices, GRALV is priced at $18.63, while NTRA trades at $259.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NTRA's P/E ratio is -144.91. In terms of profitability, GRALV's ROE is N/A, compared to NTRA's ROE of -0.15%. Regarding short-term risk, GRALV is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check NTRA's competition here
GRALV vs IQV Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, IQV has a market cap of 28.6B. Regarding current trading prices, GRALV is priced at $18.63, while IQV trades at $184.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas IQV's P/E ratio is 21.26. In terms of profitability, GRALV's ROE is N/A, compared to IQV's ROE of +0.22%. Regarding short-term risk, GRALV is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check IQV's competition here
GRALV vs ILMN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ILMN has a market cap of 25B. Regarding current trading prices, GRALV is priced at $18.63, while ILMN trades at $176.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ILMN's P/E ratio is 29.99. In terms of profitability, GRALV's ROE is N/A, compared to ILMN's ROE of +0.34%. Regarding short-term risk, GRALV is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check ILMN's competition here
GRALV vs MTD Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MTD has a market cap of 23.4B. Regarding current trading prices, GRALV is priced at $18.63, while MTD trades at $1,208.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MTD's P/E ratio is 27.16. In terms of profitability, GRALV's ROE is N/A, compared to MTD's ROE of -6.10%. Regarding short-term risk, GRALV is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check MTD's competition here
GRALV vs WAT Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, WAT has a market cap of 23.3B. Regarding current trading prices, GRALV is priced at $18.63, while WAT trades at $370.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas WAT's P/E ratio is 45.52. In terms of profitability, GRALV's ROE is N/A, compared to WAT's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check WAT's competition here
GRALV vs DGX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DGX has a market cap of 21.8B. Regarding current trading prices, GRALV is priced at $18.63, while DGX trades at $203.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DGX's P/E ratio is 21.79. In terms of profitability, GRALV's ROE is N/A, compared to DGX's ROE of +0.14%. Regarding short-term risk, GRALV is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check DGX's competition here
GRALV vs LH Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, LH has a market cap of 21.2B. Regarding current trading prices, GRALV is priced at $18.63, while LH trades at $266.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas LH's P/E ratio is 22.88. In terms of profitability, GRALV's ROE is N/A, compared to LH's ROE of +0.11%. Regarding short-term risk, GRALV is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check LH's competition here
GRALV vs EXAS Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, GRALV is priced at $18.63, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas EXAS's P/E ratio is -95.37. In terms of profitability, GRALV's ROE is N/A, compared to EXAS's ROE of -0.09%. Regarding short-term risk, GRALV is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check EXAS's competition here
GRALV vs GH Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GH has a market cap of 17.3B. Regarding current trading prices, GRALV is priced at $18.63, while GH trades at $140.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GH's P/E ratio is -38.48. In terms of profitability, GRALV's ROE is N/A, compared to GH's ROE of +1.84%. Regarding short-term risk, GRALV is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check GH's competition here
GRALV vs ILMNV Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, GRALV is priced at $18.63, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ILMNV's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to ILMNV's ROE of N/A. Regarding short-term risk, GRALV is more volatile compared to ILMNV. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check ILMNV's competition here
GRALV vs PKI Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GRALV is priced at $18.63, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PKI's P/E ratio is 41.45. In terms of profitability, GRALV's ROE is N/A, compared to PKI's ROE of +0.03%. Regarding short-term risk, GRALV is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PKI's competition here
GRALV vs MEDP Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MEDP has a market cap of 13.5B. Regarding current trading prices, GRALV is priced at $18.63, while MEDP trades at $507.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MEDP's P/E ratio is 29.78. In terms of profitability, GRALV's ROE is N/A, compared to MEDP's ROE of +1.21%. Regarding short-term risk, GRALV is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check MEDP's competition here
GRALV vs RVTY Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, RVTY has a market cap of 11.1B. Regarding current trading prices, GRALV is priced at $18.63, while RVTY trades at $106.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas RVTY's P/E ratio is 48.01. In terms of profitability, GRALV's ROE is N/A, compared to RVTY's ROE of +0.03%. Regarding short-term risk, GRALV is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check RVTY's competition here
GRALV vs ICLR Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ICLR has a market cap of 10.9B. Regarding current trading prices, GRALV is priced at $18.63, while ICLR trades at $160.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ICLR's P/E ratio is 49.03. In terms of profitability, GRALV's ROE is N/A, compared to ICLR's ROE of +0.05%. Regarding short-term risk, GRALV is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check ICLR's competition here
GRALV vs CRL Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CRL has a market cap of 9B. Regarding current trading prices, GRALV is priced at $18.63, while CRL trades at $198.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CRL's P/E ratio is -50.13. In terms of profitability, GRALV's ROE is N/A, compared to CRL's ROE of -0.06%. Regarding short-term risk, GRALV is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check CRL's competition here
GRALV vs QGEN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, QGEN has a market cap of 7.7B. Regarding current trading prices, GRALV is priced at $18.63, while QGEN trades at $38.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas QGEN's P/E ratio is 18.99. In terms of profitability, GRALV's ROE is N/A, compared to QGEN's ROE of +0.11%. Regarding short-term risk, GRALV is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check QGEN's competition here
GRALV vs TWST Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, TWST has a market cap of 5.3B. Regarding current trading prices, GRALV is priced at $18.63, while TWST trades at $91.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas TWST's P/E ratio is -64.39. In terms of profitability, GRALV's ROE is N/A, compared to TWST's ROE of -0.17%. Regarding short-term risk, GRALV is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check TWST's competition here
GRALV vs BLLN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, GRALV is priced at $18.63, while BLLN trades at $107.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BLLN's P/E ratio is 189.60. In terms of profitability, GRALV's ROE is N/A, compared to BLLN's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to BLLN. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check BLLN's competition here
GRALV vs SHC Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SHC has a market cap of 4.5B. Regarding current trading prices, GRALV is priced at $18.63, while SHC trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SHC's P/E ratio is 38.63. In terms of profitability, GRALV's ROE is N/A, compared to SHC's ROE of +0.21%. Regarding short-term risk, GRALV is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check SHC's competition here
GRALV vs SYNH Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GRALV is priced at $18.63, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GRALV's ROE is N/A, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GRALV is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check SYNH's competition here
GRALV vs RDNT Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, RDNT has a market cap of 4.4B. Regarding current trading prices, GRALV is priced at $18.63, while RDNT trades at $58.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas RDNT's P/E ratio is -330.41. In terms of profitability, GRALV's ROE is N/A, compared to RDNT's ROE of -0.01%. Regarding short-term risk, GRALV is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check RDNT's competition here
GRALV vs OLK Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GRALV is priced at $18.63, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas OLK's P/E ratio is -96.59. In terms of profitability, GRALV's ROE is N/A, compared to OLK's ROE of -0.07%. Regarding short-term risk, GRALV is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check OLK's competition here
GRALV vs GRAL Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GRAL has a market cap of 2.6B. Regarding current trading prices, GRALV is priced at $18.63, while GRAL trades at $64.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GRAL's P/E ratio is -5.93. In terms of profitability, GRALV's ROE is N/A, compared to GRAL's ROE of -0.16%. Regarding short-term risk, GRALV is more volatile compared to GRAL. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check GRAL's competition here
GRALV vs NEOG Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NEOG has a market cap of 1.9B. Regarding current trading prices, GRALV is priced at $18.63, while NEOG trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NEOG's P/E ratio is -3.15. In terms of profitability, GRALV's ROE is N/A, compared to NEOG's ROE of -0.29%. Regarding short-term risk, GRALV is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check NEOG's competition here
GRALV vs CDNA Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CDNA has a market cap of 1.3B. Regarding current trading prices, GRALV is priced at $18.63, while CDNA trades at $26.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CDNA's P/E ratio is -157.00. In terms of profitability, GRALV's ROE is N/A, compared to CDNA's ROE of -0.03%. Regarding short-term risk, GRALV is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check CDNA's competition here
GRALV vs PSNL Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PSNL has a market cap of 893.4M. Regarding current trading prices, GRALV is priced at $18.63, while PSNL trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PSNL's P/E ratio is -9.86. In terms of profitability, GRALV's ROE is N/A, compared to PSNL's ROE of -0.44%. Regarding short-term risk, GRALV is more volatile compared to PSNL. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PSNL's competition here
GRALV vs CSTL Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CSTL has a market cap of 648.5M. Regarding current trading prices, GRALV is priced at $18.63, while CSTL trades at $22.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CSTL's P/E ratio is -50.90. In terms of profitability, GRALV's ROE is N/A, compared to CSTL's ROE of -0.03%. Regarding short-term risk, GRALV is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check CSTL's competition here
GRALV vs FLGT Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, FLGT has a market cap of 516.3M. Regarding current trading prices, GRALV is priced at $18.63, while FLGT trades at $18.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas FLGT's P/E ratio is -7.57. In terms of profitability, GRALV's ROE is N/A, compared to FLGT's ROE of -0.07%. Regarding short-term risk, GRALV is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check FLGT's competition here
GRALV vs MYGN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MYGN has a market cap of 437.3M. Regarding current trading prices, GRALV is priced at $18.63, while MYGN trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MYGN's P/E ratio is -1.07. In terms of profitability, GRALV's ROE is N/A, compared to MYGN's ROE of -1.09%. Regarding short-term risk, GRALV is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check MYGN's competition here
GRALV vs CO Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GRALV is priced at $18.63, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CO's P/E ratio is 5.06. In terms of profitability, GRALV's ROE is N/A, compared to CO's ROE of +0.11%. Regarding short-term risk, GRALV is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check CO's competition here
GRALV vs PRE Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PRE has a market cap of 338.6M. Regarding current trading prices, GRALV is priced at $18.63, while PRE trades at $19.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PRE's P/E ratio is -9.67. In terms of profitability, GRALV's ROE is N/A, compared to PRE's ROE of -0.47%. Regarding short-term risk, GRALV is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PRE's competition here
GRALV vs NEO Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NEO has a market cap of 298.7M. Regarding current trading prices, GRALV is priced at $18.63, while NEO trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NEO's P/E ratio is 88.23. In terms of profitability, GRALV's ROE is N/A, compared to NEO's ROE of -0.12%. Regarding short-term risk, GRALV is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check NEO's competition here
GRALV vs FLDM Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GRALV is priced at $18.63, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GRALV's ROE is N/A, compared to FLDM's ROE of +0.17%. Regarding short-term risk, GRALV is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check FLDM's competition here
GRALV vs BDSX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BDSX has a market cap of 156M. Regarding current trading prices, GRALV is priced at $18.63, while BDSX trades at $19.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BDSX's P/E ratio is -4.84. In terms of profitability, GRALV's ROE is N/A, compared to BDSX's ROE of -21.01%. Regarding short-term risk, GRALV is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check BDSX's competition here
GRALV vs IMDX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, IMDX has a market cap of 144.1M. Regarding current trading prices, GRALV is priced at $18.63, while IMDX trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas IMDX's P/E ratio is -3.56. In terms of profitability, GRALV's ROE is N/A, compared to IMDX's ROE of +3.81%. Regarding short-term risk, GRALV is more volatile compared to IMDX. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check IMDX's competition here
GRALV vs GTH Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GRALV is priced at $18.63, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GTH's P/E ratio is -1.11. In terms of profitability, GRALV's ROE is N/A, compared to GTH's ROE of -1.01%. Regarding short-term risk, GRALV is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check GTH's competition here
GRALV vs GENE Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GRALV is priced at $18.63, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas GENE's P/E ratio is -38.25. In terms of profitability, GRALV's ROE is N/A, compared to GENE's ROE of -1.85%. Regarding short-term risk, GRALV is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check GENE's competition here
GRALV vs XGN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, XGN has a market cap of 105.2M. Regarding current trading prices, GRALV is priced at $18.63, while XGN trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas XGN's P/E ratio is -4.84. In terms of profitability, GRALV's ROE is N/A, compared to XGN's ROE of -1.14%. Regarding short-term risk, GRALV is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check XGN's competition here
GRALV vs ATLN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ATLN has a market cap of 101.4M. Regarding current trading prices, GRALV is priced at $18.63, while ATLN trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -1.00. In terms of profitability, GRALV's ROE is N/A, compared to ATLN's ROE of +38.02%. Regarding short-term risk, GRALV is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check ATLN's competition here
GRALV vs STIM Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, STIM has a market cap of 84.9M. Regarding current trading prices, GRALV is priced at $18.63, while STIM trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas STIM's P/E ratio is -2.26. In terms of profitability, GRALV's ROE is N/A, compared to STIM's ROE of -1.65%. Regarding short-term risk, GRALV is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check STIM's competition here
GRALV vs SERA Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SERA has a market cap of 70.3M. Regarding current trading prices, GRALV is priced at $18.63, while SERA trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SERA's P/E ratio is -3.02. In terms of profitability, GRALV's ROE is N/A, compared to SERA's ROE of -0.41%. Regarding short-term risk, GRALV is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check SERA's competition here
GRALV vs DRIO Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DRIO has a market cap of 43.8M. Regarding current trading prices, GRALV is priced at $18.63, while DRIO trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DRIO's P/E ratio is -0.71. In terms of profitability, GRALV's ROE is N/A, compared to DRIO's ROE of +0.93%. Regarding short-term risk, GRALV is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check DRIO's competition here
GRALV vs PRPO Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PRPO has a market cap of 41.6M. Regarding current trading prices, GRALV is priced at $18.63, while PRPO trades at $22.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PRPO's P/E ratio is -51.76. In terms of profitability, GRALV's ROE is N/A, compared to PRPO's ROE of -0.07%. Regarding short-term risk, GRALV is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PRPO's competition here
GRALV vs STRR Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, STRR has a market cap of 41.3M. Regarding current trading prices, GRALV is priced at $18.63, while STRR trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas STRR's P/E ratio is -4.49. In terms of profitability, GRALV's ROE is N/A, compared to STRR's ROE of -0.14%. Regarding short-term risk, GRALV is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check STRR's competition here
GRALV vs STRRP Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, STRRP has a market cap of 40.7M. Regarding current trading prices, GRALV is priced at $18.63, while STRRP trades at $9.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas STRRP's P/E ratio is -4.86. In terms of profitability, GRALV's ROE is N/A, compared to STRRP's ROE of -0.14%. Regarding short-term risk, GRALV is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check STRRP's competition here
GRALV vs MDXH Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MDXH has a market cap of 26.4M. Regarding current trading prices, GRALV is priced at $18.63, while MDXH trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MDXH's P/E ratio is -0.79. In terms of profitability, GRALV's ROE is N/A, compared to MDXH's ROE of +4.03%. Regarding short-term risk, GRALV is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check MDXH's competition here
GRALV vs AKU Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GRALV is priced at $18.63, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas AKU's P/E ratio is -0.13. In terms of profitability, GRALV's ROE is N/A, compared to AKU's ROE of -5.32%. Regarding short-term risk, GRALV is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check AKU's competition here
GRALV vs QUCY Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, QUCY has a market cap of 18.6M. Regarding current trading prices, GRALV is priced at $18.63, while QUCY trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas QUCY's P/E ratio is -0.07. In terms of profitability, GRALV's ROE is N/A, compared to QUCY's ROE of -2.44%. Regarding short-term risk, GRALV is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check QUCY's competition here
GRALV vs CEMI Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GRALV is priced at $18.63, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GRALV's ROE is N/A, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GRALV is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check CEMI's competition here
GRALV vs ENZ Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GRALV is priced at $18.63, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GRALV's ROE is N/A, compared to ENZ's ROE of -0.10%. Regarding short-term risk, GRALV is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check ENZ's competition here
GRALV vs PMD Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, GRALV is priced at $18.63, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PMD's P/E ratio is -5.24. In terms of profitability, GRALV's ROE is N/A, compared to PMD's ROE of -0.32%. Regarding short-term risk, GRALV is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PMD's competition here
GRALV vs ME Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, GRALV is priced at $18.63, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ME's P/E ratio is -0.03. In terms of profitability, GRALV's ROE is N/A, compared to ME's ROE of -7.71%. Regarding short-term risk, GRALV is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check ME's competition here
GRALV vs MYNZ Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, GRALV is priced at $18.63, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, GRALV's ROE is N/A, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, GRALV is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check MYNZ's competition here
GRALV vs BNGO Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BNGO has a market cap of 13.2M. Regarding current trading prices, GRALV is priced at $18.63, while BNGO trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BNGO's P/E ratio is -0.26. In terms of profitability, GRALV's ROE is N/A, compared to BNGO's ROE of -0.71%. Regarding short-term risk, GRALV is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check BNGO's competition here
GRALV vs CHEK Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, GRALV is priced at $18.63, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CHEK's P/E ratio is -0.43. In terms of profitability, GRALV's ROE is N/A, compared to CHEK's ROE of -2.26%. Regarding short-term risk, GRALV is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check CHEK's competition here
GRALV vs CNTG Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GRALV is priced at $18.63, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GRALV's ROE is N/A, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GRALV is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check CNTG's competition here
GRALV vs BNR Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BNR has a market cap of 8M. Regarding current trading prices, GRALV is priced at $18.63, while BNR trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BNR's P/E ratio is -9.12. In terms of profitability, GRALV's ROE is N/A, compared to BNR's ROE of -0.11%. Regarding short-term risk, GRALV is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check BNR's competition here
GRALV vs MBAI Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MBAI has a market cap of 7.9M. Regarding current trading prices, GRALV is priced at $18.63, while MBAI trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MBAI's P/E ratio is 2.02. In terms of profitability, GRALV's ROE is N/A, compared to MBAI's ROE of +4.17%. Regarding short-term risk, GRALV is more volatile compared to MBAI. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check MBAI's competition here
GRALV vs APDN Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, GRALV is priced at $18.63, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas APDN's P/E ratio is -0.10. In terms of profitability, GRALV's ROE is N/A, compared to APDN's ROE of -6.53%. Regarding short-term risk, GRALV is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check APDN's competition here
GRALV vs VNRX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, VNRX has a market cap of 7.1M. Regarding current trading prices, GRALV is priced at $18.63, while VNRX trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas VNRX's P/E ratio is -0.29. In terms of profitability, GRALV's ROE is N/A, compared to VNRX's ROE of +0.74%. Regarding short-term risk, GRALV is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check VNRX's competition here
GRALV vs ADVB Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ADVB has a market cap of 5.7M. Regarding current trading prices, GRALV is priced at $18.63, while ADVB trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ADVB's P/E ratio is 1.32. In terms of profitability, GRALV's ROE is N/A, compared to ADVB's ROE of -0.65%. Regarding short-term risk, GRALV is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check ADVB's competition here
GRALV vs NVTA Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GRALV is priced at $18.63, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GRALV's ROE is N/A, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GRALV is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check NVTA's competition here
GRALV vs LMDXW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GRALV is priced at $18.63, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GRALV's ROE is N/A, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GRALV is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check LMDXW's competition here
GRALV vs LMDX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GRALV is priced at $18.63, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GRALV's ROE is N/A, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GRALV is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check LMDX's competition here
GRALV vs BGLC Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BGLC has a market cap of 4.9M. Regarding current trading prices, GRALV is priced at $18.63, while BGLC trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BGLC's P/E ratio is -1.62. In terms of profitability, GRALV's ROE is N/A, compared to BGLC's ROE of -0.37%. Regarding short-term risk, GRALV is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check BGLC's competition here
GRALV vs NDRA Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NDRA has a market cap of 4M. Regarding current trading prices, GRALV is priced at $18.63, while NDRA trades at $6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NDRA's P/E ratio is -0.65. In terms of profitability, GRALV's ROE is N/A, compared to NDRA's ROE of -5.13%. Regarding short-term risk, GRALV is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check NDRA's competition here
GRALV vs BIAF Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BIAF has a market cap of 3.8M. Regarding current trading prices, GRALV is priced at $18.63, while BIAF trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BIAF's P/E ratio is -0.18. In terms of profitability, GRALV's ROE is N/A, compared to BIAF's ROE of -3.59%. Regarding short-term risk, GRALV is more volatile compared to BIAF. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check BIAF's competition here
GRALV vs BIAFW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BIAFW has a market cap of 3.8M. Regarding current trading prices, GRALV is priced at $18.63, while BIAFW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BIAFW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, GRALV is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check BIAFW's competition here
GRALV vs TRIB Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, TRIB has a market cap of 3.7M. Regarding current trading prices, GRALV is priced at $18.63, while TRIB trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas TRIB's P/E ratio is -0.18. In terms of profitability, GRALV's ROE is N/A, compared to TRIB's ROE of +0.68%. Regarding short-term risk, GRALV is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check TRIB's competition here
GRALV vs DMTK Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GRALV is priced at $18.63, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GRALV's ROE is N/A, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GRALV is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check DMTK's competition here
GRALV vs NOTV Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, GRALV is priced at $18.63, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NOTV's P/E ratio is -0.03. In terms of profitability, GRALV's ROE is N/A, compared to NOTV's ROE of -0.75%. Regarding short-term risk, GRALV is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check NOTV's competition here
GRALV vs SQL Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GRALV is priced at $18.63, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SQL's P/E ratio is -0.40. In terms of profitability, GRALV's ROE is N/A, compared to SQL's ROE of +38.02%. Regarding short-term risk, GRALV is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check SQL's competition here
GRALV vs AWH Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, GRALV is priced at $18.63, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas AWH's P/E ratio is -0.09. In terms of profitability, GRALV's ROE is N/A, compared to AWH's ROE of +2.03%. Regarding short-term risk, GRALV is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check AWH's competition here
GRALV vs INBS Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, INBS has a market cap of 1.5M. Regarding current trading prices, GRALV is priced at $18.63, while INBS trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas INBS's P/E ratio is -0.27. In terms of profitability, GRALV's ROE is N/A, compared to INBS's ROE of -1.74%. Regarding short-term risk, GRALV is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check INBS's competition here
GRALV vs HTGM Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GRALV is priced at $18.63, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GRALV's ROE is N/A, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GRALV is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check HTGM's competition here
GRALV vs BIOC Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GRALV is priced at $18.63, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GRALV's ROE is N/A, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GRALV is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check BIOC's competition here
GRALV vs ISPC Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, ISPC has a market cap of 352.7K. Regarding current trading prices, GRALV is priced at $18.63, while ISPC trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas ISPC's P/E ratio is -0.01. In terms of profitability, GRALV's ROE is N/A, compared to ISPC's ROE of -5.85%. Regarding short-term risk, GRALV is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check ISPC's competition here
GRALV vs PRENW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PRENW has a market cap of 195.6K. Regarding current trading prices, GRALV is priced at $18.63, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PRENW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to PRENW's ROE of -0.47%. Regarding short-term risk, GRALV is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PRENW's competition here
GRALV vs SQLLW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, GRALV is priced at $18.63, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, GRALV's ROE is N/A, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, GRALV is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check SQLLW's competition here
GRALV vs NDRAW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas NDRAW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, GRALV is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check NDRAW's competition here
GRALV vs CHEKZ Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, GRALV is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check CHEKZ's competition here
GRALV vs OCDX Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GRALV's ROE is N/A, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GRALV is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check OCDX's competition here
GRALV vs BNGOW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas BNGOW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, GRALV is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check BNGOW's competition here
GRALV vs PRXL Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas PRXL's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to PRXL's ROE of +0.17%. Regarding short-term risk, GRALV is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check PRXL's competition here
GRALV vs DHR-PA Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GRALV's ROE is N/A, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, GRALV is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for GRALV.Check DHR-PA's competition here
GRALV vs MEUSW Comparison June 2026
GRALV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRALV stands at 579.4M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GRALV is priced at $18.63, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRALV currently has a P/E ratio of N/A, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GRALV's ROE is N/A, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, GRALV is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for GRALV.Check MEUSW's competition here